SC 006Alternative Names: SC-006
Latest Information Update: 03 Feb 2017
At a glance
- Originator AbbVie
- Developer AbbVie; Stemcentrx
- Class Antineoplastics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 23 Jan 2017 AbbVie and Stemcentrx plan a phase I trial for Colorectal cancer (In adults, In the elderly, Refractory metastatic disease) in USA (NCT03035279)